NO20043286L - Piperidinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel - Google Patents

Piperidinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel

Info

Publication number: NO20043286L
Authority: NO; Norway
Prior art keywords: compounds; gen; active ingredient; piperidine derivative; drugs containing
Prior art date: 2002-02-08

Application number

NO20043286A

Other languages

English (en)

Other versions

NO327417B1 (no

Inventor

Hiroshi Ochiai

Yoshitaka Nishita

Tazumi Ohtani

Masaya Hamano

Original Assignee

Ono Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-08

Filing date

2004-08-06

Publication date

2004-11-08

2004-08-06 Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co

2004-11-08 Publication of NO20043286L publication Critical patent/NO20043286L/no

2009-06-22 Publication of NO327417B1 publication Critical patent/NO327417B1/no

Links

-1 Piperidine derivative compounds Chemical class 0.000 title 1
239000004480 active ingredient Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
GARSYZASUHNFPZ-UHFFFAOYSA-N 2-[4-cyano-4-[3-cyclopentyloxy-4-(difluoromethoxy)phenyl]piperidin-1-yl]acetic acid;hydrate Chemical compound O.C1CN(CC(=O)O)CCC1(C#N)C1=CC=C(OC(F)F)C(OC2CCCC2)=C1 GARSYZASUHNFPZ-UHFFFAOYSA-N 0.000 abstract 2
150000003053 piperidines Chemical class 0.000 abstract 2
MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 1
JNRDVRQSUTYTJK-UHFFFAOYSA-N 4-[3-cyclopentyloxy-4-(difluoromethoxy)phenyl]piperidine-4-carbonitrile Chemical compound FC(F)OC1=CC=C(C2(CCNCC2)C#N)C=C1OC1CCCC1 JNRDVRQSUTYTJK-UHFFFAOYSA-N 0.000 abstract 1
208000030814 Eating disease Diseases 0.000 abstract 1
208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
229910052783 alkali metal Inorganic materials 0.000 abstract 1
150000001340 alkali metals Chemical class 0.000 abstract 1
229910052784 alkaline earth metal Inorganic materials 0.000 abstract 1
150000001342 alkaline earth metals Chemical class 0.000 abstract 1
230000001539 anorectic effect Effects 0.000 abstract 1
230000003266 anti-allergic effect Effects 0.000 abstract 1
230000002456 anti-arthritic effect Effects 0.000 abstract 1
230000001088 anti-asthma Effects 0.000 abstract 1
230000000844 anti-bacterial effect Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
230000036436 anti-hiv Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000000648 anti-parkinson Effects 0.000 abstract 1
230000003356 anti-rheumatic effect Effects 0.000 abstract 1
230000000767 anti-ulcer Effects 0.000 abstract 1
239000000924 antiasthmatic agent Substances 0.000 abstract 1
239000000935 antidepressant agent Substances 0.000 abstract 1
229940005513 antidepressants Drugs 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
239000000939 antiparkinson agent Substances 0.000 abstract 1
239000003435 antirheumatic agent Substances 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
206010061428 decreased appetite Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000001553 hepatotropic effect Effects 0.000 abstract 1
230000001506 immunosuppresive effect Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
230000001777 nootropic effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Virology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)

NO20043286A 2002-02-08 2004-08-06 Piperidinderivatforbindelser, fremstilling derav, og legemidler inneholdende derivatene som den aktive bestanddel NO327417B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2002031602		2002-02-08
PCT/JP2003/001318 WO2003066590A1 (en)	2002-02-08	2003-02-07	Piperidine derivative compounds and drugs containing the compounds as the active ingredient

Publications (2)

Publication Number	Publication Date
NO20043286L true NO20043286L (no)	2004-11-08
NO327417B1 NO327417B1 (no)	2009-06-22

Family

ID=27677940

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20043286A NO327417B1 (no)	2002-02-08	2004-08-06	Piperidinderivatforbindelser, fremstilling derav, og legemidler inneholdende derivatene som den aktive bestanddel

Country Status (19)

Country	Link
US (1)	US7425567B2 (no)
EP (1)	EP1481969B1 (no)
KR (1)	KR100960062B1 (no)
CN (1)	CN1323074C (no)
AT (1)	ATE496028T1 (no)
AU (1)	AU2003207178B2 (no)
BR (1)	BR0307490A (no)
CA (1)	CA2475498C (no)
DE (1)	DE60335788D1 (no)
ES (1)	ES2356306T3 (no)
IL (1)	IL163344A (no)
MX (1)	MXPA04007688A (no)
NO (1)	NO327417B1 (no)
NZ (1)	NZ534523A (no)
PL (1)	PL215006B1 (no)
RU (1)	RU2308450C2 (no)
TW (1)	TWI305530B (no)
WO (1)	WO2003066590A1 (no)
ZA (1)	ZA200406274B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060258703A1 (en) *	2003-07-17	2006-11-16	Ono Pharmaceutical Co., Ltd.	Remedy for pruritus comprising piperidine derivative as the active ingredient
US20090182035A1 (en) *	2007-04-11	2009-07-16	Alcon Research, Ltd.	Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
TW201038295A (en) *	2009-04-17	2010-11-01	Alcon Res Ltd	Aqueous ophthalmic compositions containing anionic therapeutic agents
US20110082145A1 (en) *	2009-10-01	2011-04-07	Alcon Research, Ltd.	Olopatadine compositions and uses thereof
AR091507A1 (es)	2012-06-21	2015-02-11	Intra Cellular Therapies Inc	SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
CN105658222A (zh)	2013-06-21	2016-06-08	细胞内治疗公司	游离碱晶体
TWI904593B (zh)	2016-08-23	2025-11-11	美商賽吉醫療公司	結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
WO2021226407A1 (en)	2020-05-06	2021-11-11	Intra-Cellular Therapies, Inc.	Free base crystals
CN121449548B (zh) *	2026-01-07	2026-04-07	成都施贝康生物医药科技有限公司	一种哌啶衍生物及其药物组合物、用途以及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8904298D0 (sv) *	1989-12-21	1989-12-21	Astra Ab	New compounds
MX9301903A (es)	1992-04-02	1994-08-31	Smithkline Beecham Corp	Compuestos.
US5459151A (en) *	1993-04-30	1995-10-17	American Home Products Corporation	N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents
BR0113167A (pt) *	2000-08-11	2003-06-24	Ono Pharmaceutical Co	Derivados de piperidina e agente que compreende o derivado como ingrediente ativo

2003
- 2003-02-07 TW TW092102479A patent/TWI305530B/zh not_active IP Right Cessation
- 2003-02-07 CA CA2475498A patent/CA2475498C/en not_active Expired - Fee Related
- 2003-02-07 KR KR1020047012207A patent/KR100960062B1/ko not_active Expired - Fee Related
- 2003-02-07 ES ES03703257T patent/ES2356306T3/es not_active Expired - Lifetime
- 2003-02-07 BR BR0307490-0A patent/BR0307490A/pt not_active IP Right Cessation
- 2003-02-07 MX MXPA04007688A patent/MXPA04007688A/es active IP Right Grant
- 2003-02-07 DE DE60335788T patent/DE60335788D1/de not_active Expired - Lifetime
- 2003-02-07 AU AU2003207178A patent/AU2003207178B2/en not_active Ceased
- 2003-02-07 AT AT03703257T patent/ATE496028T1/de not_active IP Right Cessation
- 2003-02-07 CN CNB038075180A patent/CN1323074C/zh not_active Expired - Fee Related
- 2003-02-07 US US10/504,028 patent/US7425567B2/en not_active Expired - Fee Related
- 2003-02-07 RU RU2004126953/04A patent/RU2308450C2/ru not_active IP Right Cessation
- 2003-02-07 WO PCT/JP2003/001318 patent/WO2003066590A1/ja not_active Ceased
- 2003-02-07 PL PL371729A patent/PL215006B1/pl unknown
- 2003-02-07 EP EP03703257A patent/EP1481969B1/en not_active Expired - Lifetime
- 2003-02-07 NZ NZ534523A patent/NZ534523A/en not_active IP Right Cessation
2004
- 2004-08-04 IL IL163344A patent/IL163344A/en not_active IP Right Cessation
- 2004-08-05 ZA ZA2004/06274A patent/ZA200406274B/en unknown
- 2004-08-06 NO NO20043286A patent/NO327417B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
RU2004126953A (ru)	2006-01-27
DE60335788D1 (de)	2011-03-03
AU2003207178A1 (en)	2003-09-02
CN1323074C (zh)	2007-06-27
EP1481969A1 (en)	2004-12-01
KR20040082416A (ko)	2004-09-24
IL163344A (en)	2011-04-28
NZ534523A (en)	2006-10-27
RU2308450C2 (ru)	2007-10-20
TWI305530B (en)	2009-01-21
ATE496028T1 (de)	2011-02-15
KR100960062B1 (ko)	2010-05-31
PL371729A1 (en)	2005-06-27
NO327417B1 (no)	2009-06-22
AU2003207178B2 (en)	2008-10-23
MXPA04007688A (es)	2004-11-10
WO2003066590A1 (en)	2003-08-14
CA2475498A1 (en)	2003-08-14
US7425567B2 (en)	2008-09-16
BR0307490A (pt)	2004-12-28
PL215006B1 (pl)	2013-10-31
ZA200406274B (en)	2005-11-30
US20050080107A1 (en)	2005-04-14
EP1481969B1 (en)	2011-01-19
CN1649841A (zh)	2005-08-03
ES2356306T3 (es)	2011-04-06
CA2475498C (en)	2011-05-10
EP1481969A4 (en)	2006-01-11
TW200302723A (en)	2003-08-16

Legal Events

Date	Code	Title	Description
2015-09-28	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
ATE223378T1 (de)	2002-09-15	Prolineamid-derivate
DE60142891D1 (de)	2010-10-07	Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
NO945084L (no)	1995-07-03	Substituerte heterocykliske karboksylsyreamider, deres fremstilling og anvendelse som legemiddel
CA2445145A1 (en)	2002-11-21	Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
TR200200579T2 (tr)	2002-12-23	Amino-tirazolpiridin türevleri.
EP1400529A4 (en)	2007-12-19	GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
NO962543D0 (no)	1996-06-14	Cykliske amid-derivater som neurokinin A-antagonister
NO984878L (no)	1998-12-29	Fremstilling og anvendelse som medikamenter av 3-alkoksypyridin-2-karboksylsyreamidestere
PL377478A1 (pl)	2006-02-06	Cykloalkenowe kwasy dikarboksylowe jako środki przeciwzapalne, immunomodulujące oraz antyproliferacyjne
NO20043286L (no)	2004-11-08	Piperidinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
EA200100916A1 (ru)	2002-02-28	Лекарственное средство, содержащее производное сульфопиранозилацилглицерина
DE60107832D1 (en)	2005-01-20	Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
EP1211251A4 (en)	2003-04-09	CHROMONE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF
SE0102057D0 (sv)	2001-06-08	New Salts I
EP1174421A4 (en)	2003-04-23	3-AMIDINOBENZENESULFONAMIDE DERIVATIVES, MEDICAL PREPARATIONS CONTAINING IT AND INTERMEDIATE PRODUCTS IN THEIR PRODUCTION
NO20013601L (no)	2001-09-11	Nye morfolinobenzamidsalter
ATE316788T1 (de)	2006-02-15	Medikament gegen pulmonale herzprobleme
WO2003018564A1 (en)	2003-03-06	Vascular wall-selective acat inhibitor
EP1466909A4 (en)	2005-12-07	HALOGENBENZYLAMINOPROPIONSÄUREDERIVATE
EP1464636A4 (en)	2006-01-11	NEW SUBSTANCE WITH ANTITUM EFFECT / INFLAMMATORY EFFECT
DK1237866T3 (da)	2005-10-10	Amycomycin, en fremgangsmåde til dets fremstilling og dets anvendelse som et lægemiddel
AU2003236180A1 (en)	2003-10-13	Hydroxymorpholinone derivative and medicinal use thereof